Shares of Eisai Co., Ltd (OTCMKTS:ESALY) have been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $79.00.
A number of research analysts have recently commented on the stock. Citigroup raised shares of Eisai from a “sell” rating to a “neutral” rating in a research report on Monday, August 5th. Daiwa Capital Markets downgraded shares of Eisai from a “neutral” rating to a “sell” rating in a report on Tuesday, September 17th. Jefferies Financial Group initiated coverage on shares of Eisai in a report on Tuesday, September 24th. They issued a “buy” rating for the company. Finally, Zacks Investment Research raised shares of Eisai from a “hold” rating to a “strong-buy” rating and set a $79.00 price objective for the company in a report on Tuesday.
Shares of OTCMKTS ESALY traded up $0.13 during mid-day trading on Wednesday, reaching $65.86. The company had a trading volume of 2,417 shares, compared to its average volume of 30,288. The firm has a 50 day simple moving average of $60.27 and a two-hundred day simple moving average of $56.30. Eisai has a 52-week low of $48.52 and a 52-week high of $90.41. The company has a current ratio of 1.91, a quick ratio of 1.66 and a debt-to-equity ratio of 0.14. The stock has a market cap of $19.07 billion, a P/E ratio of 33.10, a PEG ratio of 2.03 and a beta of 0.35.
Eisai (OTCMKTS:ESALY) last posted its earnings results on Wednesday, October 30th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.59 by ($0.42). Eisai had a return on equity of 9.07% and a net margin of 9.10%. The firm had revenue of $1.35 billion for the quarter. On average, equities analysts expect that Eisai will post 2.59 EPS for the current year.
Eisai Co, Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It develops Fycompa, an antiepileptic drug in the neurology area that is approved as an adjunctive therapy for partial-onset seizures in Japan, the United States, Europe, and Asia. The company is also approved for use as monotherapy for the treatment of partial onset seizures in the United States; and as an adjunctive therapy for primary generalized tonic-clonic seizures in Japan, the United States, Europe, and Asia.
Recommended Story: What is the LIBOR?
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.